MRPL13 and Familial prostate cancer: The cBioPortal database revealed that the highest incidence of gene alterations in MRPL13 is in ovarian cancer, while it is also amplified in the majority of pan-cancer patients, including those with breast cancer, esophageal cancer, liver cancer, uterine cancer, pancreatic cancer, gastric adenocarcinoma, prostate cancer, head and neck squamous cell carcinoma, bladder cancer, and lung adenocarcinoma.